During the past decade, Aran Eye Associates conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Aran Eye Associates" #1 collaborator was "Carl Zeiss Meditec, Inc." with 1 trials as a collaborator, "Optovue" with 1 trials as a collaborator and "ThromboGenics" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Aran Eye Associates" are "Macular Degeneration" (2 trials) and "Vitreomacular Adhesion" (1 trials). Many other conditions were trialed in "Aran Eye Associates" in a lesser frequency.

Most popular intervention types in "Aran Eye Associates" are "Device" (2 trials). Other intervention types were less common.

The name of intervention was led by "Rheopheresis blood filtration" (2 trials). Other intervention names were less common.

The vast majority of trials in "Aran Eye Associates" are 3 trials for "All" genders.

Currently, there are NaN active trials in "Aran Eye Associates". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Aran Eye Associates, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Aran Eye Associates, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".